-A short-term topical impetigo treatment from Ferrer Healthcare, Spain
-It is a new drug approved from FDA and EMA and also will be released in Korea in 2022
Bukwang announced that Ozanex cream(ozenoxacin) from Ferrer, Spain got approval from the Ministry of Food and Drug Safety.
Ozanex is the first non fluoroquinolone topical treatment for staphylococcus aureus(S. aureus) and Streptococcus pyogenes(S. pyogenes) in adults and young children. It is also effective in short-term topical treatment for impetigo.
Ozanex has a superior antibacterial effect, so it can treat impetigo within 5 days. Also, it can be treated from 2 month-old children to adults with its excellent safety. It will be released in Korea in 2022 and already used in the US, EU, and Canada with approval.
Bukwang said, “we can offer a new treatment option for impetigo through Ozanex with an effective short-term treatment and safety. Also Bukwang will continue doing its best to improve patients’ quality of life by introducing new drugs such as Ozanex.
Bukwang has strengthened its position with Ozanex in dermatological portfolios under license agreements such as ‘Nadixa cream’ for acne and ‘Dermofix cream’ as well as ‘Dermofix gel’ for fungal infection.